Previous close | 91.57 |
Open | 90.89 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 90.20 - 91.50 |
52-week range | 76.29 - 99.65 |
Volume | |
Avg. volume | 5,967 |
Market cap | 165.332M |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 4.22 |
EPS (TTM) | 0.22 |
Earnings date | 24 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.